BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25220258)

  • 1. Carboxypeptidase E is a novel modulator of RANKL-induced osteoclast differentiation.
    Kim HJ; Hong J; Yoon HJ; Yoon YR; Kim SY
    Mol Cells; 2014 Sep; 37(9):685-90. PubMed ID: 25220258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
    Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
    Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The paired-box homeodomain transcription factor Pax6 binds to the upstream region of the TRAP gene promoter and suppresses receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation.
    Kogawa M; Hisatake K; Atkins GJ; Findlay DM; Enoki Y; Sato T; Gray PC; Kanesaki-Yatsuka Y; Anderson PH; Wada S; Kato N; Fukuda A; Katayama S; Tsujimoto M; Yoda T; Suda T; Okazaki Y; Matsumoto M
    J Biol Chem; 2013 Oct; 288(43):31299-312. PubMed ID: 23990468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLAT negatively regulates RANKL-induced osteoclast differentiation.
    Youn BU; Kim K; Kim JH; Lee J; Moon JB; Kim I; Park YW; Kim N
    Mol Cells; 2013 Sep; 36(3):252-7. PubMed ID: 23996528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
    Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
    BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2E-Decene-4,6-diyn-1-ol-acetate inhibits osteoclastogenesis through mitogen-activated protein kinase-c-Fos-NFATc1 signalling pathways.
    Park YR; Su XD; Shrestha SK; Yang SY; Soh Y
    Clin Exp Pharmacol Physiol; 2022 Mar; 49(3):341-349. PubMed ID: 34729812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression.
    Han SY; Kim YK
    Am J Chin Med; 2019; 47(2):439-455. PubMed ID: 30827151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
    Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
    Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.
    Jules J; Zhang P; Ashley JW; Wei S; Shi Z; Liu J; Michalek SM; Feng X
    J Biol Chem; 2012 May; 287(19):15728-38. PubMed ID: 22416138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade.
    Moon JB; Kim JH; Kim K; Youn BU; Ko A; Lee SY; Kim N
    J Immunol; 2012 Jan; 188(1):163-9. PubMed ID: 22131333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MafB negatively regulates RANKL-mediated osteoclast differentiation.
    Kim K; Kim JH; Lee J; Jin HM; Kook H; Kim KK; Lee SY; Kim N
    Blood; 2007 Apr; 109(8):3253-9. PubMed ID: 17158225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esculetin attenuates receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation through c-Fos/nuclear factor of activated T-cells c1 signaling pathway.
    Baek JM; Park SH; Cheon YH; Ahn SJ; Lee MS; Oh J; Kim JY
    Biochem Biophys Res Commun; 2015 May; 461(2):334-41. PubMed ID: 25887803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NADPH oxidase gp91
    Kang IS; Kim C
    Sci Rep; 2016 Nov; 6():38014. PubMed ID: 27897222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.
    Hasegawa H; Kido S; Tomomura M; Fujimoto K; Ohi M; Kiyomura M; Kanegae H; Inaba A; Sakagami H; Tomomura A
    J Biol Chem; 2010 Aug; 285(33):25448-57. PubMed ID: 20547767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR.
    Kim JH; Kim K; Youn BU; Jin HM; Kim N
    Cell Signal; 2010 Sep; 22(9):1341-9. PubMed ID: 20466061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1.
    Yamashita T; Yao Z; Li F; Zhang Q; Badell IR; Schwarz EM; Takeshita S; Wagner EF; Noda M; Matsuo K; Xing L; Boyce BF
    J Biol Chem; 2007 Jun; 282(25):18245-18253. PubMed ID: 17485464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parthenolide inhibits osteoclast differentiation and bone resorbing activity by down-regulation of NFATc1 induction and c-Fos stability, during RANKL-mediated osteoclastogenesis.
    Kim JY; Cheon YH; Yoon KH; Lee MS; Oh J
    BMB Rep; 2014 Aug; 47(8):451-6. PubMed ID: 24314143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.